Catch up on coverage from the first day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.

Colleen Cotton, MD, shared clinical tips in treating HS in pediatric patients at the annual SPD Pre-AAD Meeting.

In addition to Taylor, several other new leaders have been appointed to key roles within the AAD to help drive its mission of advancing dermatology.

Alexandra P. Charrow, MD, FAAD, shares insights on the link between dermatology and irritable bowel disease at the AAD Annual Meeting.

Along with his session insights on diet and chronic spontaneous urticaria, Friedman shares tips for navigating the largest dermatology conference in the US.

Ahead of the annual meeting, Dermatology Times spoke with Draelos about why she looks forward to the meeting each year.

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Orlando, Florida.

Deepti Gupta, MD, discussed the importance of lasers at the Society for Pediatric Dermatology 37th Annual Pre-AAD Annual Meeting.

Among the many sessions to be held at the American Academy of Dermatology Annual Meeting in Orlando, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

At AAAAI/WAO 2025, Bernstein explored new findings on rilzabrutinib and dupilumab in CSU, highlighting treatment gaps and future therapies.

Single-use packaging and excess sample distribution contribute to environmental harm, necessitating a shift in industry practices.

Phase 3 trial results presented at AAAAI/WAO 2025 highlight dupilumab's efficacy in reducing itch severity and urticaria activity in CSU patients.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of March.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a female patient aged 12 years with moderate AD that had been worsening over the past several months.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a woman aged 25 years who presented with erythematous and scaly patches on her face, neck, and upper trunk.